Rumor has it the CAR-T specialists at Cellectis are considering a potential sale, and partner Pfizer, already riding its checkbook into the world of immuno-oncology, could be a suitor.
The World Health Assembly passed a resolution Monday calling for improved vaccine pricing transparency and for more affordable vaccines, with more than 60 countries expressing support.
One year ago, Pfizer finally bowed out of the fight to buy AstraZeneca. The hostile bid was, well, quite hostile. And ever since, both companies have operated in the shadow of that failed deal.
When China said it would lift price caps on drugs, the move was heralded as welcome relief for drugmakers. But as Bloomberg reports, the optimism may have been premature. Yes, the price caps won't affect most drugs beginning June 1. But foreign drugmakers are facing pressure to cut their prices voluntarily--more than ever.
The speculation is building this week that Pfizer will either attempt another megadeal with GlaxoSmithKline or another run on AstraZeneca. Either would cut Pfizer's tax rate and give it some products to salve its various ills, lackluster stock price and poor performing portfolio. But the new thinking, like in the last 24 hours, is that smaller deals, perhaps a buyout of Shire or even Perrigo, or both, are better bets.
Hospira is voluntarily recalling 181,704 bags of magnesium sulfate in 5% dextrose injections because labels on the immediate container may have barcodes indicating that it is instead the blood thinner heparin.
Pfizer needs to make a deal--or several. It's obviously amenable to another megamerger, given that it tried to snap up AstraZeneca for more than $100 billion last year. So why not GlaxoSmithKline?
The latest market chatter is that Pfizer, rebuffed in its quest to acquire AstraZeneca last year, is taking a hard look at GlaxoSmithKline, and one analyst says it might be a good idea.
India's policy regarding intellectual property protection has bounced back once again to deny an MNC patent challenged by a local drugmaker. This one was filed by the local unit of Fresenius Kabi Oncology against a Pfizer patent.
Pfizer and Bristol-Myers Squibb's new-age anticoagulant, Eliquis, has been ramping up after a slow start. But Johnson & Johnson, maker of market leader Xarelto, need not worry, thanks to that med's wide base of indications and hefty clinical trials program.